
News|Articles|October 1, 2006
High-dose statin therapy displays benefit in preventing cardiovascular events compared with standard doses
Intensive lipid lowering with high-dose 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) provides a significant benefit over standard-dose statin therapy in preventing nonfatal cardiovascular outcomes and also may reduce the incidence of cardiovascular death, according to results of a meta-analysis published in the Journal of the American College of Cardiology.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Older drug could slash blood transfusions during surgeries | ASH 2025
2
Sanofi’s Qfitlia seems favorable for hemophilia with easier dosing and broad coverage | ASH 2025
3
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
4
Breakthrough treatments offer hope for melanoma patients
5




















































